Quantumleap Healthcare Collaborative
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2005-01-01
- Employees
- 11
- Market Cap
- -
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
- Conditions
- Ductal Carcinoma in Situ
- Interventions
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- QuantumLeap Healthcare Collaborative
- Target Recruit Count
- 400
- Registration Number
- NCT06075953
- Locations
- 🇺🇸
Berkeley Outpatient Center, Berkeley, California, United States
🇺🇸UCSF, San Francisco, California, United States
🇺🇸Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
PRE-I-SPY Phase I/Ib Oncology Platform Program
- Conditions
- Metastatic Breast CancerMetastaticHormone Receptor-positive Breast CancerHormone Receptor Negative Breast CarcinomaHER2 Low Breast CancerHER2 Low Breast CarcinomaHER2-positive Breast CancerMetastatic CancerHER2-negative Breast CancerSolid Tumor, Adult
- Interventions
- First Posted Date
- 2023-05-22
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- QuantumLeap Healthcare Collaborative
- Target Recruit Count
- 124
- Registration Number
- NCT05868226
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸The University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
- Conditions
- Metastatic Breast CancerMetastatic Gastrointestinal Carcinoid TumorHER-2 Protein OverexpressionHER2-positive Breast CancerHER2 LowSYD-985SYD985Vic-trastuzumab DuocarmazineMetastatic CancerMetastatic
- Interventions
- Drug: Vic-trastuzumab duocarmazine (SYD985) + paclitaxel
- First Posted Date
- 2020-10-26
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- QuantumLeap Healthcare Collaborative
- Registration Number
- NCT04602117
- Locations
- 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
- Conditions
- COVID-19
- Interventions
- Biological: dornase alfaBiological: IC14Biological: narsoplimab
- First Posted Date
- 2020-07-27
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- QuantumLeap Healthcare Collaborative
- Target Recruit Count
- 1500
- Registration Number
- NCT04488081
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸UC Davis Medical Center, Davis, California, United States
🇺🇸UC Irvine Medical Center, Irvine, California, United States
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Conditions
- HER2-negative Breast CancerHormone Receptor Positive TumorAngiosarcomaTNBC - Triple-Negative Breast CancerBreast NeoplasmsBreast TumorsHER2-positive Breast CancerHormone Receptor Negative TumorBreast CancerEarly-stage Breast Cancer
- Interventions
- Drug: Standard TherapyDrug: AMG 386 with or without TrastuzumabDrug: AMG 479 (Ganitumab) plus MetforminDrug: SYD985 ([vic-]trastuzumab duocarmazine)Drug: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumabDrug: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumabDrug: Datopotamab deruxtecan + DurvalumabDrug: Rilvegostomig + TDXdDrug: AMG 386 and Trastuzumab
- First Posted Date
- 2010-01-05
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- QuantumLeap Healthcare Collaborative
- Target Recruit Count
- 5000
- Registration Number
- NCT01042379
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Mayo Clinic - Scottsdale, Scottsdale, Arizona, United States
🇺🇸University of Arizona, Tucson, Arizona, United States